Purpose of the Procedure
- Predicting patient response to anti-EGFR antibody therapies.
- Identifying specific mutations in the RAS oncogene family.
- Enabling personalized and precision oncology treatment.
Book KRAS and NRAS Mutation Test | Lahalak Medical Platform
This genetic test is essential for metastatic colorectal cancer patients to predict response to anti-EGFR therapies. It empowers oncologists to personalize treatment plans, ensuring maximum efficacy and avoiding unnecessary medication side effects.
Scientific name: KRAS and NRAS Mutation Testing
An advanced genetic test analyzing mutations in the RAS gene family to predict response to anti-EGFR antibody therapies in metastatic colorectal cancer, enabling precision medicine and targeted treatment.
Service type
Genetic Testing
Duration
7-10 working days
Fasting
Fasting is not required
Included Services
- Blood sample collection or tissue processing
- Genetic sequencing analysis
- Detailed medical result report
Medical Service Information
Target Groups
- Patients diagnosed with metastatic colorectal cancer.
- Individuals being screened for targeted therapy eligibility.
- Oncologists requiring genetic profiles for treatment planning.
Understanding Results
- Wild-type result: Indicates the patient may benefit from targeted therapy.
- Mutant result: Suggests resistance to certain anti-EGFR medications.
Conditions & Notices
- Medical history report preferred
- May require tumor tissue sample (biopsy)
Medical services you might also like
